CytomX Therapeutics, Inc. (CTMX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about CytomX Therapeutics, Inc. (CTMX)
Go deeper and ask any question about CTMX
Company Performance
Current Price
as of Sep 13, 2024$1.23
P/E Ratio
8.83
Market Cap
$96.08M
Description
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Metrics
Overview
- HQSouth San Francisco, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerCTMX
- Price$1.23-1.60%
Trading Information
- Market Cap$96.08M
- Float98.31%
- Average Daily Volume (1m)509,183
- Average Daily Volume (3m)901,201
- EPS$0.14
Company
- Revenue$119.57M
- Rev Growth (1yr)1.58%
- Net Income-$6.53M
- Gross Margin98.17%
- EBITDA Margin-31.83%
- EBITDA-$7.99M
- EV-$21.88M
- EV/Revenue-0.18
- P/E8.83
- P/S0.87
Documents
SEC Filings
Factset Street Account
Earnings Calls
Factset